Physician profile
Christine Frissora
NPI 1861589954
$123,077.93
in general payments reported to CMS, 2019-2025
21 companies · $34K in 2025
The $34K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,627 · 2020: $11K · 2021: $22K · 2022: $9,684 · 2023: $17K · 2024: $23K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $46K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $8,161 · Food and Beverage: $6,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $46,300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Travel and Lodging | $8,160.89 |
| Food and Beverage | $6,204.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $102,415.00 | 2019-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $12,010.55 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,601.69 | 2019-2024 | Trulance |
| Ardelyx, INC. | $2,051.82 | 2022-2025 | Ibsrela |
| Abbvie INC. | $1,217.02 | 2019-2025 | |
| Mahana Therapeutics, INC. | $877.07 | 2022 | |
| Alfasigma USA, INC. | $500.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $359.55 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $240.75 | 2024-2025 | Tremfya, Stelara |
| Vibrant Gastro, INC. | $125.00 | 2025 | Vibrant Starter Kit |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $122.89 | 2021-2023 | Sutab |
| Genzyme Corporation | $102.08 | 2024-2025 | |
| Avion Pharmaceuticals | $70.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.43 | 2023 | Dificid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $58.59 | 2024 | |
| Lilly USA, LLC | $38.58 | 2025 | Omvoh |
| Amgen INC. | $35.90 | 2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $28.41 | 2024 | |
| Pfizer INC. | $20.53 | 2023 | |
| Redhill Biopharma INC. | $14.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Frissora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.